the aid library

LIST OPTIONS

Filter

8433

Guidelines on Clinical Management of Chikungunya Fever

World Health Organization (WHO), Regional Office for South-East Asia (2007) C_WHO

The socioeconomic factors and public health inadequacies that facilitated the rapid spread of this infection continue to exist. As it is a new and emerging disease it has not received sufficient coverage yet in the medical curricula of Member States. Specific treatment is not available, and there is... more

Download (431)

View PDF (516)

Study provides data behind new MDR-TB guidance

Dall, C. CIDRAP (2018) CC

A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments. The meta-analysis... more

External Link

The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia

Schutte, C.; Forsythe, S.; Fedes Mdala, J.; et al. (2020) CC2

PLoS ONE 15(1): e0228135. The introduction of “Treat All” (TA) has been promoted to increase the effectiveness of HIV/AIDS treatment by having patients initiate antiretroviral therapy at an earlier stage of their illness. The impact of introducing TA on the unit cost of treatment has been less ... more

Download (272)

View PDF (299)

Vietnam: National Action Plan on Combating Drug Resistance in the period from 2013 - 2020

Ministry of Health Vietnam (2013) C2

In Vietnam, most of the examination and treatment facilities are facing with of spread of bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at alarming level. The burden of drug resistance is increasing due to the increasing cost of treatment, prolonged t... more

Download (1555)

View PDF (3636)

MDR-TB Weight-Based Dosing Chart for Children

Sentinel Project (2013) C1

Therapy for MDR-TB is extremely long, complex and burdensome to both patients and health care systems. A single diagnosis can require two years of treatment, or longer. When treating children, there are significant additional barriers treating children with MDR-TB. There is limited data on the pharm... more

Download (204)

View PDF (477)

COPD Foundation Educational Materials

COPD Foundation COPD Foundation (2024) CC2

The COPD Foundation's website provides a range of educational resources and downloadable materials aimed at helping patients, caregivers, and healthcare professionals learn more about COPD, including information on prevention, treatment, and disease management.

External Link

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

External Link

Ebola: What Every Health Care Professional Should Know

University of Alabama at Birmingham (UAB) School of Nursing (2014)

The course has an emphasis on health care in the US: "health care professionals need to understand this virus as more patients in the United States are confirmed to have EVD and patients are being transported to the US for treatment". Does anyone know of similar online courses (in English and/or Fre... more

External Link

BMJ's Coronavirus (covid-19) Hub

British Medical Journal (2020) CC

BMJ has created a free resource on SARS-CoV-2 and covid-19 to inform diagnosis and treatment, and to promote the wellbeing and safety of staff and patients during this extremely stressful and challenging period. BMJ’s dedicated covid-19 hub not only draws on the latest peer reviewed research, n... more

External Link

Buruli ulcer: wound care and rehabilitation

Frimpong, M.; F. S.Sarfo, M. Sarpong Duah, et al. Dove Medical Press Limited (2016) C1

Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim... more

Download (675)

View PDF (443)

Community- Based Management of Acute Malnutrition (CMAM)

World Vision International (2017) C1

Community-Based Management of Acute Malnutrition (CMAM) is a decentralised community-based approach to treating acute malnutrition. Treatment is matched to the nutritional and clinical needs of the child, with the majority children receiving treatment at home using ready-to-use foods. In-patient car... more

Download (710)

View PDF (762)

GUIDELINES FOR GOOD CLINICAL LABORATORY PRACTICES (GCLP)

Indian Council of Medical Research (ICMR) (2008) C1

Guidelines for Good Clinical Laboratory Practices (GCLP) outlines the principles and procedures to be followed by medical laboratories involved in clinical research and/or patient care so as to provide quality data which can be used for health research and patient treatment. As the use of laboratory... more

Download (360)

View PDF (263)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (359)

View PDF (373)

The Core Elements of Outpatient Antibiotic Stewardship

Centers for Disease Control and Prevention CDC (2019) C_CDC

The Core Elements of Outpatient Antibiotic Stewardship provides a framework for antibiotic stewardship for outpatient clinicians and facilities that routinely provide antibiotic treatment. This report augments existing guidance for other clinical settings. In 2014 and 2015, respectively, CDC release... more

Download (1106)

View PDF (580)

Guidelines for Pharmacovigilance and Medicine Information System in Rwanda

Ministry of Health, Rwanda (2011) C2

The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to... more

External Link

New Therapeutics for Chagas Disease: Charting a Course to Drug Approval

Man, A. & Segal, F. Intechopen (2022) CC

DOI: 10.5772/intechopen.102891Little progress has been made since the 1960s and 19. 70s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and opera... more

Download (432)

View PDF (552)

HIV and tuberculosis co-infection programmes

Avert Avert (2019) C2

People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people. It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB... more

Download (210)

View PDF (381)

COPD Foundation Educational Materials - EPOC 201: Más allá de lo básico

COPD Foundation COPD Foundation (2022) CC2

The document provides comprehensive guidance for people with COPD, covering treatment and medication management, oxygen therapy, mucus control, exercise, smoking cessation, nutrition, associated conditions, and strategies to prevent exacerbations. It emphasizes patient education, self-management, an... more

Download (541)

View PDF (748)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (290)

View PDF (546)

occupied Palestinian territory COVID-19 Response Plan (27 March 2020)

UN Office for the Coordination of Humanitarian Affairs (OCHA) (2020) C_WHO

The primary focus of the plan continues to be prevention, preparedness and treatment of the the Novel Coronavirus (COVID-19) outbreak. Central to the plan are the following overall objectives: To prevent further transmission of COVID-19 in the oPt; To provide adequate care for patients aff... more